Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock Has Average Price Target of $23.57 According to Analysts

by · The Cerbat Gem

Shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Free Report) have been assigned an average rating of “Reduce” from the eleven analysts that are covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a sell recommendation and six have given a hold recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $23.57.

Several equities analysts recently commented on FMS shares. Truist Financial set a $25.00 target price on Fresenius Medical Care AG & Co. KGaA in a report on Wednesday, August 5th. Citigroup reaffirmed a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Friday, July 17th. BNP Paribas Exane cut Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating and set a $19.90 price objective for the company. in a research report on Tuesday, July 28th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, August 4th. Finally, Zacks Research upgraded Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th.

View Our Latest Stock Report on Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co. KGaA Stock Down 0.2%

Shares of NYSE:FMS opened at $22.36 on Friday. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of $20.02 and a fifty-two week high of $27.64. The firm’s 50 day moving average price is $23.52 and its 200 day moving average price is $22.95. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.43. The stock has a market cap of $12.01 billion, a price-to-earnings ratio of 11.58, a price-to-earnings-growth ratio of 4.18 and a beta of 0.76.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.62 by $0.04. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.83% and a return on equity of 9.28%. The company had revenue of $5.55 billion during the quarter, compared to analysts’ expectations of $5.48 billion. As a group, equities research analysts predict that Fresenius Medical Care AG & Co. KGaA will post 2.25 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Fresenius Medical Care AG & Co. KGaA

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Pzena Investment Management LLC increased its stake in Fresenius Medical Care AG & Co. KGaA by 2.0% in the first quarter. Pzena Investment Management LLC now owns 15,052,822 shares of the company’s stock valued at $339,592,000 after purchasing an additional 299,986 shares during the last quarter. Moran Wealth Management LLC lifted its position in shares of Fresenius Medical Care AG & Co. KGaA by 31.5% during the 1st quarter. Moran Wealth Management LLC now owns 347,773 shares of the company’s stock worth $7,846,000 after buying an additional 83,311 shares during the last quarter. Quantinno Capital Management LP lifted its position in shares of Fresenius Medical Care AG & Co. KGaA by 15.7% during the 1st quarter. Quantinno Capital Management LP now owns 341,343 shares of the company’s stock worth $7,701,000 after buying an additional 46,428 shares during the last quarter. Royal Bank of Canada boosted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 479.2% in the 1st quarter. Royal Bank of Canada now owns 216,861 shares of the company’s stock valued at $4,893,000 after buying an additional 179,418 shares in the last quarter. Finally, Assetmark Inc. boosted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 190.7% in the 1st quarter. Assetmark Inc. now owns 132,320 shares of the company’s stock valued at $2,985,000 after buying an additional 86,798 shares in the last quarter. 8.37% of the stock is owned by institutional investors and hedge funds.

Fresenius Medical Care AG & Co. KGaA Company Profile

(Get Free Report)

Fresenius Medical Care AG & Co KGaA is a Germany-based health care company focused on kidney disease and dialysis services. The company provides hemodialysis and peritoneal dialysis treatments through a global network of outpatient dialysis clinics and supports patients with related care and medical services.

In addition to operating dialysis centers, Fresenius Medical Care develops and manufactures products used in renal care. Its portfolio includes dialysis machines, dialyzers, bloodlines, concentrates, solutions, pharmaceuticals and other disposable supplies.

Recommended Stories